Mutual funds significantly increased their allocation to the healthcare sector in February 2026, making it their fourth-largest exposure. This overweight stance, exceeding the BSE 200 benchmark, is driven by strong earnings visibility, export potential in pharmaceuticals, and rising insurance penetration. Experts suggest moderate exposure for investors, balancing stability with sectoral concentration risks.
